<p>Genmab A/S（OTCMKTS:GNMSF - 获取免费报告）在周三的午盘交易中股价下跌了 5.9%。该公司的股价最低曾达到 280.85 美元，最后交易价格为 280.85 美元。午盘交易中成交了 63 股，较平均交易量 467 股下降了 87%。该股票此前收盘价为 298.38 美元。</p>
<h2>Genmab A/S 股价下跌 5.9%</h2>
<p>该公司的市值为 172.9 亿美元，市盈率为 18.14，贝塔值为 0.94。该公司的 50 日简单移动平均线为 284.61 美元，200 日简单移动平均线为 305.58 美元。公司的债务与股本比率为 0.86，速动比率为 2.01，流动比率为 2.02。</p>
<p>Genmab A/S（OTCMKTS:GNMSF - 获取免费报告）最近一次发布财报是在 2 月 17 日，报告显示该季度每股收益（EPS）为 0.55 美元，低于分析师一致预期的 3.10 美元，差距为 2.55 美元。Genmab A/S 的股本回报率为 17.35%，净利润率为 25.89%。该公司在该季度的收入为 10.6 亿美元，而分析师预期为 10.5 亿美元。</p>
<h2>关于 Genmab A/S</h2>
<p>（获取免费报告）</p>
<p>Genmab A/S 是一家生物技术公司，专注于抗体治疗药物的发现和开发，以治疗癌症及其他严重疾病。该公司的核心专长在于其专有的抗体平台，包括 DuoBody®、HexaBody®和 HexElect®，这些平台能够设计和工程化新型双特异性和增强效应的抗体。Genmab 的科学驱动方法将先进的蛋白质工程与肿瘤生物学的见解相结合，以生成能够激活免疫系统、干扰疾病通路并提供潜在安全性和疗效优势的候选药物。</p>
<p>Genmab 成立于 1999 年，总部位于丹麦哥本哈根，已发展成为一家全球性组织，在荷兰乌得勒支设有研发设施，并在美国设有商业和临床支持办公室。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Genmab A/S</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Genmab A/S 吗？</h2>
<p>在考虑 Genmab A/S 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Genmab A/S 并不在名单上。</p>
<p>虽然 Genmab A/S 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

GMAB

<p>Genmab A/S (OTCMKTS:GNMSF) 的股价下跌了 5.9%，至 280.85 美元，交易量较平均水平下降了 87%。该公司报告第一季度每股收益为 0.55 美元，低于预期的 3.10 美元，尽管收入为 10.6 亿美元。Genmab 专注于癌症治疗的抗体疗法，市值为 172.9 亿美元。分析师目前对该股票的评级为持有，但建议其他股票可能是更好的投资选择</p>

<p>Genmab A/S (OTCMKTS:GNMSF - Get Free Report) shares traded down 5.9% during mid-day trading on Wednesday . The company traded as low as $280.85 and last traded at $280.85. 63 shares were traded during mid-day trading, a decline of 87% from the average session volume of 467 shares. The stock had previously closed at $298.38.</p>
<div class="lb-trans"><p>Genmab A/S（OTCMKTS:GNMSF - 获取免费报告）在周三的午盘交易中股价下跌了 5.9%。该公司的股价最低曾达到 280.85 美元，最后交易价格为 280.85 美元。午盘交易中成交了 63 股，较平均交易量 467 股下降了 87%。该股票此前收盘价为 298.38 美元。</p>
</div><h2>Genmab A/S Stock Down 5.9%</h2>
<div class="lb-trans"><h2>Genmab A/S 股价下跌 5.9%</h2>
</div><p>The firm has a market capitalization of $17.29 billion, a price-to-earnings ratio of 18.14 and a beta of 0.94. The business has a 50 day simple moving average of $284.61 and a 200-day simple moving average of $305.58. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02.</p>
<div class="lb-trans"><p>该公司的市值为 172.9 亿美元，市盈率为 18.14，贝塔值为 0.94。该公司的 50 日简单移动平均线为 284.61 美元，200 日简单移动平均线为 305.58 美元。公司的债务与股本比率为 0.86，速动比率为 2.01，流动比率为 2.02。</p>
</div><p>Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.10 by ($2.55). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.05 billion.</p>
<div class="lb-trans"><p>Genmab A/S（OTCMKTS:GNMSF - 获取免费报告）最近一次发布财报是在 2 月 17 日，报告显示该季度每股收益（EPS）为 0.55 美元，低于分析师一致预期的 3.10 美元，差距为 2.55 美元。Genmab A/S 的股本回报率为 17.35%，净利润率为 25.89%。该公司在该季度的收入为 10.6 亿美元，而分析师预期为 10.5 亿美元。</p>
</div><h2>About Genmab A/S</h2>
<div class="lb-trans"><h2>关于 Genmab A/S</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company's core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab's science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.</p>
<div class="lb-trans"><p>Genmab A/S 是一家生物技术公司，专注于抗体治疗药物的发现和开发，以治疗癌症及其他严重疾病。该公司的核心专长在于其专有的抗体平台，包括 DuoBody®、HexaBody®和 HexElect®，这些平台能够设计和工程化新型双特异性和增强效应的抗体。Genmab 的科学驱动方法将先进的蛋白质工程与肿瘤生物学的见解相结合，以生成能够激活免疫系统、干扰疾病通路并提供潜在安全性和疗效优势的候选药物。</p>
</div><p>Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.</p>
<div class="lb-trans"><p>Genmab 成立于 1999 年，总部位于丹麦哥本哈根，已发展成为一家全球性组织，在荷兰乌得勒支设有研发设施，并在美国设有商业和临床支持办公室。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Genmab A/S</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Genmab A/S</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Genmab A/S Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Genmab A/S 吗？</h2>
</div><p>Before you consider Genmab A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Genmab A/S 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Genmab A/S 并不在名单上。</p>
</div><p>While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Genmab A/S 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Genmab A/S (OTCMKTS:GNMSF) 股价下跌 5.9% - 接下来会发生什么？